


Prescribing Information

Prescribing Information
28 tablets containing oestradiol valerate 2 mg, the last 12 also containing levonorgestrel 75 micrograms. Indications: Hormone replacement therapy for the treatment of the climacteric syndrome. Dosage and administration: Menstruating patients begin treatment on the 5th day of menstruation. Other patients may start at any time. One tablet daily continuously. Contraindications, warnings, etc. Contra-indications: Pregnancy, severe disturbances of liver function, jaundice or general puritus of pregnancy. Dubin-Johnson syndrome, Rotor syndrome, existing or previous thromboembolism, sickle-cell anaemia, suspected or existing hormone-dependent disorders or tumours of the uterus and breast, congenital disturbances of lipid metabolism, a history of herpes gestationis (also known as pemphigoid gestationis), obsolerosis with detenoration during pregnancy. Warnings/side-effects: Hormonal contraception should be stopped. Reported symptoms include anxiety, increased appetite, bloating, breast symptoms, cardiac symptoms, depressive symptoms, anxiety, increased appetite, bloating, breast symptoms, cardiac symptoms, depressive symptoms, dizziness, dyspepsia, leg pains and swelling, altered libido, nausea, rashes, vomiting and altered weight. Cholestasis is possible in predisposed patients. Carefully monitor multiple sclerosis, epilepsy, diabetes, hypertension, porphyria, tetany and otosclerosis. **Precautions and special**

HRT in a single daily tablet

information: Before treatment, exclude pregnancy. If the expected bleeding fails to occur at about 28-day intervals, stop treatment and exclude pregnancy. Stop treatment at once if there are frequent and unusually severe headaches, first migraine or possible prodromata of vascular occlusion, or if trauma, illness or impending surgery entails a risk of thrombosis, if jaundice or pregnancy occurs, or blood pressure rises significantly. In patients with mild chronic liver disease, check liver function every 8-12 weeks. Examination of the pelvic organs, endometrium, breasts and blood-pressure is advised before and periodically during treatment. Investigate irregular bleeding. Pharmaceutical precautions: Store in cool, dry conditions. Shelf-life five years. Legal category POM Basic NHS Cost per pack of 3 x 28 tablets: £13.98 PL 0053/02!9 PL Holder: Schering Health Care Ltd. Burgess Hill, West Sussex RH15 9NE. Nuvelle is a trademark of Schering AG. NUV Nov 1992. References: 1. Eisen, S.A. et al., Arch. Intern. Med., 1990; 150: 1881–84. 2. Schneider, W.H.F. & Spona, J., Acta. Obstet Gynecol. Scand., 1977; Suppl. 65: 39–43. 3. Klopper, A., Br. Med. J., 1976; 2: 414–416. 4. Whitehead, M.I., Acta. Obstet. Gynecol. Scand. Suppl., 1986; 134: 81–91. 5. Whitehead, M.I. et al., J. Reprod. Med., 1982; 27 (suppl. 8): 539–48.

Schering



CLASSIFIED ADVERTISEMENTS

Classified Advertisements are welcomed and should be sent to: The Advertising Sales Executive, Royal College of General Practitioners, 14 Princes Gate, Hyde Park, London SW7 1PU. Telephone: 071-581 3232. Fax: 071-225 3047. Copy must be received three weeks before the 1st of the month of issue to ensure inclusion. Every effort will be made to include advertisements received after this date but publication cannot be guaranteed and the advertisement may have to be held over to the following issue. The publisher will not be responsible for any error in the insertion of, or omission to insert, any advertisement. The charge for space in this section is £10.00 per single column centimetre, plus £10.00 if a box number is required, plus VAT at 17.5%. Fellows, Members and Associates of the Royal College of General Practitioners may claim a 10% reduction. Replies to box numbers should be sent to the above address, with the box number on the envelope. The inclusion of an advertisement in this Journal does not imply any recommendation and the Editor reserves the right to refuse, amend or withdraw any advertisement without explanation. All recruitment advertisements in this section are open to both men and women.

COURSES

TEACHING THE MEDICAL AUDIT TEACHERS

17/18/19 March, 16/17/18 June & 27/28/29 October 1993

Venue: RCGP

A three day course in medical audit for those who teach it. The course is designed to present the subject of medical audit and to examine three related topics: standard setting, the collection and analysis of data and the management of change within the practice while also considering how to present and teach these subjects to colleagues. PGEA for 3 days - one day each of Service Management, Disease Management and Health Promotion & Prevention of Illness or zero-rated Section 63.

DATA HANDLING FOR MEDICAL AUDIT

28/29 April, 22/23 September & 1/2 December 1993

Venue: RCGP

A two day course training in the technical skills involved in collecting and digesting medical audit information. The course is suitable both for interested general practitioners and their staff and for those working with Medical Audit Advisory Groups. PGEA has been granted for 2 days under Service Management.

For full details of 1993 dates and fees contact

RCGP Conferences on 071-823 9703

COURSES

3 Day Refresher Course

Disability/Neurology;
Community Care Act/Information Technology;
Smoking Cessation/Communication Skills/
Health Promotion

10 - 12 February 1993

THREE FULL DAYS PGEA applied for

Apply; Mrs M Johnson, Postgraduate Centre, Stoke Mandeville Hospital, Aylesbury, Bucks, HP21 8AL, Tel: 0296 315425

Cost £50 per day; Cheques payable to: "The Stoke Mandeville Education Fund"



MRCGP DCH DRCOG

Success in exams is vital for improving your career prospects. To be sure of passing at your first attempt you need to be well prepared. PasTest has 20 years specialist experience in helping doctors to pass their exams and we can help you to be successful.

Plenty of practice is vital. Our high quality books and courses will help you to obtain the maximum revision in the minimum of time by testing your knowledge and identifying your weak subject areas in time for further study.

Start your revision now. Write or telephone us for full details, information is sent by return of post.

PasTest Service, Dept. GP, Freepost, Knutsford, Cheshire WA16 7BR

Tel: 0565 - 755226

WHY NOT FRAME YOUR MRCGP OR FRCGP CERTIFICATE?

Teak or Black hand-made frames to the exact measurement of your certificate.

Total cost per frame £16.95 incl. p&p (UK only).

Make cheque payable to:

The Professional Framing Company, c/o Royal College of General Practitioners, 14 Princes Gate, London SW7 1PU

Quoting: Ref 3

Prescription for giving value for money


Government Health Ministers – and the Treasury – are reported to be concerned about the continuing increase in prescribing costs incurred by Britain's family doctors. The main reasons for this are as follows:

- As people get older they require more medicines. There have been significant increases in the numbers of people living beyond 75 and, in particular, beyond 85. A recent survey showed that of a 51 million increase in prescriptions written by GPs over a ten-year period, more than 49 million (i.e. 96 per cent) were for patients of pensionable age.¹
- As a direct consequence of the imposition of cash-limits and some aspects of the NHS Reforms many hospitals have 'transferred' significant prescribing costs to GPs.

Advances in scientific knowledge have led to more effective and safer medicines. But, as the chart demonstrates, the major element in the rise in the NHS Medicines Bill is due to increased volume – not to price rises or the use of newer more expensive products.² And the UK spends less per head and easily the least amount on new medicines.

The Government, as part of its reform programme for the NHS, has encouraged GPs to set up clinics to help identify patients requiring preventive medicine – treatments for high blood pressure and late-onset diabetes for example. More people requiring medicines have been identified; but the costs will be more than offset by longer-term savings. The future need for hospital care will be reduced because heart attacks, strokes or blindness in literally thousands of patients will be prevented.

Chart shows annual rise of pharmaceutical expenditures with figures showing prescription medicines sales and cost of new products per head, 1991.



The underlying purpose behind the NHS Reforms was to provide a wider and more cost-effective service to patients.

Extra costs incurred today will yield far greater savings in the future.

That is giving real value for money

1 Trends in usage of prescription medicines by the elderly and very elderly between 1977 and 1988, ABPI, 1990.
2 Growth in prescription medicines expenditure – an international comparison. ABPI, 1992.
Publications available from ABPI, 12 Whitehall, London SW1A 2DY



THE BRITISH PHARMACEUTICAL INDUSTRY.
HELPING TO KEEP BRITAIN HEALTHY

BRITAIN'S ARTHRITICS



different way of taking oral NSAID therapy.

New FELDENE MELT* breaks the mould of traditional tablets and capsules. When placed on the tongue FELDENE MELT dissolves in seconds to provide 24 hour control of symptoms. In this way patients can benefit from night and day relief of pain, reduced inflammation and improved mobility.

Because it's such a pleasant way of taking medicine, you may find many of your patients prefer FELDENE MELT to conventional capsules or tablets. Try them and see.



Prescribing Information For FELDENE MELT (piroxicam):

Indications: Adults: Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout and acute musculoskeletal disorders. Elderly: As with other NSAIDs elderly patients should be closely supervised. Children: FELDENE MELT is not recommended in children. For treatment of juvenile chronic arthritis (Still's disease) please see oral data sheet. Dosage: Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis normal starting and maintenance dosage 20mg once daily. Long-term use of 30mg daily or more carries an increased risk of gastro-intestinal side-effects. Acute gout - 40mg daily in single or divided doses for up to 7 days. Acute musculoskeletal disorders - 40mg daily, in single or divided doses, for the first 2 days, 20mg daily for the remainder of the 7 to 14 days' treatment. Contra-indications: Active peptic ulceration or history of recurrent ulceration. Hypersensitivity to FELDENE,

aspirin or other NSAIDs. Warnings: Pregnancy, loctation. Precautions: Significant renal, hepatic or cardiac insufficiency. Patients with phenylketonuria - each Melt tablet contains 0.14 mg phenylalanine. Drug Interactions: Monitor patients on concurrent anticoagulants, lithium or diuretic therapy. Concurrent use of aspirin or other NSAIDs is not advised. Side-Effects: Gastro-intestinal symptoms; if peptic ulceration or gastro-intestinal bleeding occurs withdraw FELDENE. Oedema, mainly ankle. Skin rashes. CNS effects, including headaches and dizziness. Rare cases of renal and hepatic abnormalities have been reported. Haematological reactions including thrombocytopenia and anaemia and hypersensitivity reactions such as bronchospasm and anaphylaxis have been reported very rarely. Package Quantities and Basic NHS Cost: FELDENE MELT tablets 20mg, pack of 28, £11-97 (PL 0057/0352). Full information on request. References 1. Data on file Pfizer Limited. 2 Boardman PL et al. Eur J Rheumatol Inflam (1983); 6 (1): 73-83.

*Trade Mark

MELTS IN SECONDS. RELIEVES PAIN FOR 24 HOURS.2







Division of Pfizer Limited